# CHECKMATE 920 (NCT02982954)

> A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02982954
- Phase: PHASE4
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Renal Cell Carcinoma
- Interventions: Nivolumab; Ipilimumab
- Enrollment: 211
- Primary outcome: Number of Participants With High Grade (Grade 3-4) Immune Mediated Adverse Events (IMAEs)
- Primary outcome: Number of Participants With High Grade (Grade 5) Immune Mediated Adverse Events (IMAEs)

## Commentary we found

- Podcasts: 2
- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=checkmate-920-nct02982954